Coronary stent containing recombinant human cellular repressor of E1 A-stimulated genes (hCREG) glycoprotein and preparation method for coronary stent

A glycoprotein, coronary artery technology, applied in the field of coronary stents containing recombinant hCREG glycoprotein and its preparation, can solve problems such as low expression level, and achieve the effects of inhibiting cell proliferation, promoting healing, and promoting re-endothelialization

What is AI technical title?
AI technical title is built by PatSnap AI team. It summarizes the technical point description of the patent document.
A glycoprotein, coronary artery technology, applied in the field of coronary stents containing recombinant hCREG glycoprotein and its preparation, can solve problems such as low expression level, and achieve the effects of inhibiting cell proliferation, promoting healing, and promoting re-endothelialization

CN102309781AInactive Publication Date: 2012-01-11LEPU MEDICAL TECH (BEIJING) CO LTD

5 Cites 8 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.

Viewing Examples

Smart Image

Examples

Experimental program

Comparison scheme

Effect test

Embodiment 1

[0049] Example 1 Preparation of recombinant hCREG glycoprotein and its coronary stent

[0050] 1. Preparation of Nanoporous Recombinant hCREG Glycoprotein Elution Scaffold

[0051] 1.1 Preparation of recombinant hCREG glycoprotein

[0052] 1.1.1 Construction of recombinant gene vector Since 1999, the mRNA differential display technology was used to successfully clone the human CREG gene from the human internal thoracic artery VSMCs cultured in vitro for the first time, and the hCREG open reading frame with a stop codon mutation was amplified by RT-PCR technology Frame, the hCREG RT-PCR primers of the stop codon mutation are as follows: the upstream primer is 5'-aa ggatccatggccgggctatcccgc-3' (SEQ ID NO.1), and the downstream primer is: 5'-gc gaattcGcactgaactgtgacatttaatattcttctgg-3' (SEQ ID NO.2 ), where the capital letter represents the stop codon for the C / G mutation.

[0053] The recombinant human CREG protein expression vector pcDNA3.1-his / myc-hCREG with his tag protein ...

Embodiment 2

[0064] Embodiment 2 Preparation of drug-protein combined scaffold

[0065] The surface of the coronary stent in this embodiment is uniformly distributed with recombinant hCREG glycoprotein and rapamycin. The drug rapamycin is distributed on the outer layer of the stent, and the recombinant hCREG glycoprotein is distributed in the lumen of the stent.

[0066] Stent equipped with nanopores: the stent is made of 316L medical stainless steel matrix, and the surface is uniformly equipped with nanopores of about 500nm.

[0067] Preparation of three-sided rapamycin drug stent: Accurately prepare 1% rapamycin drug with acetone solution. The inner surface of the stent is protected, and rapamycin is sprayed on the outer surface of the stent.

[0068] Preparation of CREG protein-eluting scaffold: The recombinant hCREG glycoprotein is fixed to the inner lumen of the scaffold by using the principle of physical adsorption of nanopores. The solvent is a sodium carbonate buffer solution wi...

Embodiment 3

[0069] Example 3 Preparation of double-drug protein combined scaffold

[0070] The surface of the coronary stent in this embodiment is uniformly distributed with recombinant hCREG glycoprotein, rapamycin and paclitaxel. Rapamycin and paclitaxel were distributed on the outer surface of the stent, and recombinant hCREG glycoprotein was distributed in the lumen of the stent.

[0071] Stent equipped with nanopores: the stent is made of 316L medical stainless steel matrix, and the surface is uniformly equipped with nanopores of about 500nm.

[0072] Prepare a three-sided rapamycin drug stent: protect the inner surface of the stent, spray rapamycin and paclitaxel on the outer surface of the stent, the drug concentration is 1%, the drug solvent adopts tetrahydrofuran, and the space between rapamycin and paclitaxel is The ratio is 1:1.

[0073] Preparation of CREG protein-eluting scaffold: The recombinant hCREG glycoprotein is fixed to the inner lumen of the scaffold by using the pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

PUM

Login to View More

Abstract

The invention provides a coronary stent containing a recombinant human cellular repressor of E1 A-stimulated genes (hCREG) glycoprotein. The surface of the coronary stent is uniformly coated with the recombinant hCREG glycoprotein. After the coronary stent is implanted into a human body, the proliferation of vascular smooth muscle cells is restrained by the sustained release of hCREG glycoprotein components carried by the stent, the re-endothelialization of a vascular wall is promoted, and the damaged vascular wall is quickly cured, so that intraluminal thrombi caused by medical equipment are prevented, and the time used by a patient to take anti-thrombotic medicaments and blood platelet medicaments postoperatively is shortened.

Description

technical field [0001] The invention relates to a bioengineering and preparation of bioengineering medical equipment, in particular to a coronary stent containing recombinant hCREG glycoprotein and a preparation method thereof. It belongs to the field of bioengineering and interventional medical devices implanted in the body. Background technique [0002] Cardiovascular disease is a serious threat to human health. According to the WHO report, the number of deaths due to cardiovascular disease is as high as 30% of the total number of deaths in the world every year. Percutaneous coronary intervention (PCI) is currently one of the main treatment methods for coronary heart disease. More than 1.5 million patients with coronary heart disease worldwide receive PCI treatment every year, but 10-70% of postoperative vascular revascularization The incidence of restenosis (RS) significantly reduced the benefit of surgery. How to effectively prevent and control the occurrence of RS and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

Application Information

Patent Timeline

11 Jan 2012

Publication

CN102309781A

IPC: A61L27/54; A61L27/56; A61L27/34

Inventors: 韩雅玲; 邓捷